Gériatrie et Psychologie Neuropsychiatrie du Vieillissement
MENUDiagnostic value of cerebrospinal fluid alpha-synuclein in dementia with Lewy body Volume 16, issue 3, Septembre 2018
Tables
1 Hôpitaux Universitaires de Strasbourg, Laboratoire de biochimie et biologie moléculaire ; CNRS, Laboratoire de neurosciences cognitives et adaptatives (LNCA), UMR7364, Strasbourg, France
2 Hôpitaux Universitaires de Strasbourg, Centre mémoire de ressource et de recherche (CMRR), Hôpital de jour, Pôle de gériatrie ; CNRS, Laboratoire ICube UMR 7357 ; Fédération de médecine translationnelle de Strasbourg (FMTS), Équipe IMIS/Neurocrypto, Strasbourg, France
* Tirés à part
- Key words: Lewy body disease, Alzheimer's disease, cerebrospinal fluid, alpha-synuclein, differential diagnosis
- DOI : 10.1684/pnv.2018.0750
- Page(s) : 305-10
- Published in: 2018
Dementia with Lewy body (DLB) is the second most common form of dementia after Alzheimer's disease (AD), accounting for 15% to 20% of neuropathologically defined cases. Two-thirds of the patients affected are not or misdiagnosed. In this review, we evaluate the discriminatory power of cerebrospinal fluid (CSF) alpha-synuclein by focusing more specifically on differential diagnosis between DLB and AD. Alpha-synuclein assay in the CSF has an interest in the discrimination between DLB and AD but not in segregation between DLB and healthy elderly subjects. The development of biomarkers such as phospho-alpha-synuclein and oligomeric alpha-synuclein should help to reinforce this discrimination power.